A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2004
12/21/2004	US6833378 Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders.
12/21/2004	US6833376 5-aminoalkyl and 5-aminocarbonyl substituted indole derivative useful for treatment of psychosis in a mammal
12/21/2004	US6833372 A hormone inhibitors of gonadotropin releasing hormone, an antigonadotropins, new drug compound contains a furanyl 2-carboxylic acid -(2,4-dimethoxy-pyrimidin-5-yl)-amide groups
12/21/2004	US6833371 Contacting cell with a sodium channel-inhibiting amount of a compound comprising a pyrazolopyrimidine moiety for decreasing ion flow through a voltage-dependent sodium channel in a cell
12/21/2004	US6833370 Heterocycle substituted aminoazacycles useful as central nervous system agents
12/21/2004	US6833368 Tackykinin antagonist
12/21/2004	US6833353 Inhibiting matrix metalloprotease (MMP) production using such as tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxy-ascomycin
12/21/2004	US6833269 Stem cell culture product
12/21/2004	US6833243 For diagnosis of psychosis/schizophrenia via detection of mutant allele
12/21/2004	US6833140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
12/21/2004	US6833130 Recombinant microorganisms expressing an oligosaccharide receptor mimic
12/21/2004	CA2134674C Gaba and l-glutamic acid analogs for antiseizure treatment
12/21/2004	CA2079968C Mono-fluorinated derivatives of n-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
12/16/2004	WO2004108907A1 Nerve cell obtained by electrically pulse-treating es cell
12/16/2004	WO2004108760A2 Improved secretion of neublastin
12/16/2004	WO2004108729A1 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF
12/16/2004	WO2004108728A1 Cannabinoid receptor ligands and uses thereof
12/16/2004	WO2004108724A1 Tricyclic compound
12/16/2004	WO2004108706A1 Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
12/16/2004	WO2004108705A1 3-fluoro-piperidines as nmda/nr2b antagonists
12/16/2004	WO2004108701A1 Imidazole derivatives as glutmate receptor antagonists
12/16/2004	WO2004108688A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
12/16/2004	WO2004108682A2 Tetrahydroisoquinolines as antagonists of the 5ht1b receptor
12/16/2004	WO2004108674A1 Amino alcohol derivative, medicinal composition containing the same, and uses of these
12/16/2004	WO2004108671A1 Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
12/16/2004	WO2004108661A1 Amidino compounds as cysteine protease inhibitors
12/16/2004	WO2004108150A1 Agent for reducing effect of alcohol toxicity
12/16/2004	WO2004108149A1 Sobering agent
12/16/2004	WO2004108141A2 Bach-o-protein coupled receptor releated methods
12/16/2004	WO2004108137A1 A method of treating an anxiety disorder
12/16/2004	WO2004108133A2 Modulators of vr1 receptor
12/16/2004	WO2004108119A2 Use of atp or derivatives in medicine
12/16/2004	WO2004091646A3 Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
12/16/2004	WO2004089882A3 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
12/16/2004	WO2004089353A3 Methods for treatment of parkinson's disease
12/16/2004	WO2004089352A3 Pharmaceutical combination for the treatment of spasticity and/or pain
12/16/2004	WO2004087116A3 Drug combination for motor dysfunction in parkinson's disease
12/16/2004	WO2004080448A3 Use of nep-associated molecules for treating non-immunogenic, non-hypertensive civilisation diseases
12/16/2004	WO2004072029A3 Pyrazolopyridazines useful as inhibitors of protein kinases
12/16/2004	WO2004064832A3 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
12/16/2004	WO2004058287A3 Methods of treating neurological conditions with hematopoeitic growth factors
12/16/2004	WO2003071922A3 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
12/16/2004	WO2003066666A3 Compositions and methods for treatment of vitamin d deficiency
12/16/2004	WO2003027254A3 15625 receptor, a novel g-protein coupled receptor
12/16/2004	US20040254385 Process for the preparation of citalopram hydrobromide
12/16/2004	US20040254382 Imidazolyl derivatives as corticotropin releasing factor inhibitors
12/16/2004	US20040254378 2-Methanesulfone group; Side effect reduction; Nonsteroidal Antiinflammatory
12/16/2004	US20040254376 Cyclic amidine derivative
12/16/2004	US20040254375 Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor
12/16/2004	US20040254372 Poly(adenosine 5'-diphospho-ribose)polymerase (PARP) inhibitor; for treating or preventing neurological, genetic, autoimmune, nervous system, cardiovascular disorders, cancer; such as myocardial infarction, angina pectoris and cardiogenic shock
12/16/2004	US20040254371 New benzothiazine and benzothiadiazine compounds
12/16/2004	US20040254370 Peroxisome proliferators activated receptor regulator; useful for hypoglycemia, hypolipidemia, preventing and/or treatment of diseases associating metabolic disorders, atherosclerosis, cardiovascular diseases, syndrome x, cholestrol
12/16/2004	US20040254350 Immunomodulatory protein for use in diagnosis, treatment, and prevention of immune system, neurological, developmental, muscle and cell proliferative disorders
12/16/2004	US20040254348 Opiate receptor therapeutic protein/peptides for use in pain relief and management
12/16/2004	US20040254344 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
12/16/2004	US20040254342 Substrates and assays for beta-secretase
12/16/2004	US20040254341 Human aspartyl protease peptide for use in identifying modulators for treatment and prevention of neurodegenerative and nervous system disorders; enzyme inhibitors
12/16/2004	US20040254338 Melanin-concentrating hormone antagonists
12/16/2004	US20040254249 Nonsteroidal antiinflammatory agents
12/16/2004	US20040254240 Anti-cancer nitro- and thia-fatty acids
12/16/2004	US20040254233 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
12/16/2004	US20040254216 Inhibitors of p38
12/16/2004	US20040254213 Use of bicyclo compounds for treating alzheimer's disease
12/16/2004	US20040254212 Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
12/16/2004	US20040254210 Pharmaceutical compositions comprising colloidal silicon dioxide
12/16/2004	US20040254207 linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group; also containing an opioid analgesic; enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.
12/16/2004	US20040254200 Antiinflammatory agents; controlling interleukins, tumor necrosis factor; antiarthritic agents; immunosuppressants
12/16/2004	US20040254198 Respiratory system disorders; asthma; chronic obstructive pulmonary disease
12/16/2004	US20040254193 Novel tetrahydroquinolines
12/16/2004	US20040254192 2,4,5-trisubstituded thiazolyl derivatives and their antiinflammatory activity
12/16/2004	US20040254189 Jnk inhibitors
12/16/2004	US20040254186 Pyridylfurans and pyrroles as raf kinase inhibitors
12/16/2004	US20040254184 Psychological disorders; antidepressants; anxiolytic agents; analgesics; antiinflammatory agents; central nervous system disorders
12/16/2004	US20040254182 Enhanced propertied pharmaceuticals
12/16/2004	US20040254179 Central nervous system disorders; psycholgical disorders; antiepi;eptic agents; schizophrenia; Alzheimer's disease; cognition activators; analgesics
12/16/2004	US20040254177 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
12/16/2004	US20040254176 Hypotensive agents; cardiovascular disorders; antidiabetic agents; skin disorders;kidney disorders; headaches; vision defects; strokes; synergistic mixture of amlodipine, benazepril and hydrochlorothiazide; oral administering
12/16/2004	US20040254175 Antitumor agenst; thrombosis; arteriosclerosis; cardiovascular disorders; antiinflammatory agents
12/16/2004	US20040254161 New benzothiazine and benzothiadiazine compounds
12/16/2004	US20040254148 Pharmaceutical composition effective in treatment of mechanical allodynia, screening method of potential compound as said pharmaceutical composition, inspection method of mechanical allodynia, and treatment method of mechanical allodynia
12/16/2004	US20040254145 Benzylaminosulfonic Acid or portion or analogue linked to a carbohydrate or glycomimetic for modulating processes mediated by selectin binding such as autoimmune and inflammatory diseases, shock and reperfusion injuries
12/16/2004	US20040254116 Contactor tissue with transforming growth factor kinase receptors; modulate cell proliferation
12/16/2004	US20040254114 Genetic engineering
12/16/2004	US20040254110 Methods for diagnosing and treating Alzheimer's disease
12/16/2004	US20040254093 Antiinflammatory agents; cardiovascular disorders; anticancer agents; antidiabetic agents
12/16/2004	US20040253709 Schistosoma protein for use in treatment of organ-specific autoimmune diseases
12/16/2004	US20040253706 Substrates and assays for beta-secretase
12/16/2004	US20040253684 Nucleotide sequences coding mambrane associated guanylate kinase for use in treatment and prevention of nervous system, blood, sleep and behavioral disorders
12/16/2004	US20040253647 Evaluating modulators effectiveness as treatment for alzheimer's via quantifying amyloid precursor protein peptide cleavage products present after exposure agonist/antagonist
12/16/2004	US20040253588 Cytochrome p450 monooxygenase for use in identifying modulators for treatment, diagnosis and prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, gastrointestinal and liver disorders
12/16/2004	US20040253322 Mixtures of clinoptilolite, plant extracts and vitamins, used for attenuation of neuropathic pain associated with diabetes or prevent deposition of immunoglobulin on axons
12/16/2004	US20040253301 Transdermal therapeutic system comprising a reservoir type pressure sensitive adhesive layer and a back layer with uni-directional resilience
12/16/2004	US20040253276 Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization
12/16/2004	US20040253245 Modulating an immune response by administering a modulator of Notch intracellular domain protease activity, including modulators of presenilin and presenilin-dependent gamma secretase activity; immunotherapy; treatment of Alzheimer's disease
12/16/2004	US20040253244 Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
12/16/2004	CA2528924A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
12/16/2004	CA2528756A1 Tetrahydroisoquinolines as antagonists of the 5ht1b receptor
12/16/2004	CA2528497A1 Tricyclic compound
12/16/2004	CA2527914A1 Improved secretion of neublastin
12/16/2004	CA2526694A1 Amidino compounds as cysteine protease inhibitors

1 ... 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 ... 1833